摘要
目的探讨HBME1和CD10免疫标记在甲状腺癌诊断中的作用。方法应用免疫组织化学方法检测82例甲状腺病变组织中HBME1和CD10的存在情况。结果正常甲状腺组织均没有HBME1和CD10的表达,良性病变没有一例HBME1和CD10同时阳性;HBME1和CD10在乳头状癌、滤泡癌、滤泡性腺瘤和结节性甲状腺肿的阳性率分别为33/35(94%)、6/7(86%)、6/20(30%)、5/20(25%)和15/35(43%)、2/7(29%)、1/20(5%)、0。两者在甲状腺癌的表达均明显高于良性病变(均P<0.001),两者在乳头状癌与滤泡癌的表达均没有明显的差异(均P>0.05)。结论HBME1和CD10免疫标记阳性提示恶性,但不表示就是乳头状癌或滤泡癌。
Objective To study the value of HBME1 and CD10 immunostain in the diagnosis of thyroid carcinomas.Methods We examined HBME1 and CD10 in in 82 thyroid lesions （including 35 papillary carcinomas,7 follicular carcinoma,20 follicular adenomas and 20 nodular goiters） by immunohistoehemistry. Results HBME1 and CD10 were not detected in normal thyroid tissue, none of benign lesion was positive for all two markers. The expression of HBBME1 and CD10 in papillary carcinomas , follicular carcinomas, follicular adenomas and nodular goiters were 33/35 （ 94 % ）, 6/7 （ 86 % ）, 6/20 （30%）, 5/20 （ 25 % ） and 15/35 （ 43 % ）, 2/7 （29%） ,1/20（5%）and 0 respectively. Conclusion HBME1 and CD10 positivity indicates malignancy but not papillary differentiation. Both markers were valuable in diagnosis of thyroid nodular.
出处
《中国实验诊断学》
2006年第5期466-468,共3页
Chinese Journal of Laboratory Diagnosis
